Aegerion Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aegerion Pharmaceuticals, Inc.
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
In championing Forte Medical’s precision diagnostics technology to improve the quality of urine test samples, 2022 Rising Leader Giovanna Forte has often had to confront market access hurdles. It has not dented her drive to secure widespread adoption of money-saving and outcomes-boosting devices.
Antiverse co-founder and CEO Murat Tunaboylu, one of In Vivo’s 2022 Rising Leaders, on defining success and why software engineers should consider a career transition to life sciences.
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.